The three drugs that are attempting to receive reimbursement as a treatment for pediatric·adolescent patients with atopic dermatitis - Dupixent (dupilumab), Cibinqo (abrocitinib), and Rinvoq (upadacitinib) – are expected to be approved for reimbursement within the first half of the year.

With all 3 drugs passing the Health Insurance Review and Assessment Service’s deliberations, only the pricing negotiation process with NHIS remains for the three drugs. This is why analysts believe the drugs will be listed for reimbursement within June this year.

In the case of Sanofi’s Dupxient Prefilled Inj (200·300mg), the drug’s reimbursement adequacy was accepted by HIRA’s Drug Reimbur